These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Caroli P; Sandler I; Matteucci F; De Giorgi U; Uccelli L; Celli M; Foca F; Barone D; Romeo A; Sarnelli A; Paganelli G Eur J Nucl Med Mol Imaging; 2018 Nov; 45(12):2035-2044. PubMed ID: 29922948 [TBL] [Abstract][Full Text] [Related]
43. Target volume definition in high-risk prostate cancer patients using sentinel node SPECT/CT and 18 F-choline PET/CT. Vees H; Steiner C; Dipasquale G; Chouiter A; Zilli T; Velazquez M; Namy S; Ratib O; Buchegger F; Miralbell R Radiat Oncol; 2012 Aug; 7():134. PubMed ID: 22873771 [TBL] [Abstract][Full Text] [Related]
44. Pfister D; Haidl F; Nestler T; Verburg F; Schmidt M; Wittersheim M; Steib F; Heidenreich A BJU Int; 2020 Dec; 126(6):679-683. PubMed ID: 32531840 [TBL] [Abstract][Full Text] [Related]
45. Comparison of Schwenck J; Rempp H; Reischl G; Kruck S; Stenzl A; Nikolaou K; Pfannenberg C; la Fougère C Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):92-101. PubMed ID: 27557844 [TBL] [Abstract][Full Text] [Related]
46. Efficacy of early imaging with Özülker F Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):100-105. PubMed ID: 30514659 [TBL] [Abstract][Full Text] [Related]
47. Accuracy of Mandel P; Tilki D; Chun FK; Pristupa E; Graefen M; Klutmann S; Budäus L; Steuber T Eur Urol Focus; 2020 Jan; 6(1):71-73. PubMed ID: 30049657 [TBL] [Abstract][Full Text] [Related]
48. Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate Cancer. Park SY; Zacharias C; Harrison C; Fan RE; Kunder C; Hatami N; Giesel F; Ghanouni P; Daniel B; Loening AM; Sonn GA; Iagaru A Radiology; 2018 Aug; 288(2):495-505. PubMed ID: 29786490 [TBL] [Abstract][Full Text] [Related]
49. Value of PET/CT and MR lymphography in treatment of prostate cancer patients with lymph node metastases. Fortuin AS; Deserno WM; Meijer HJ; Jager GJ; Takahashi S; Debats OA; Reske SN; Schick C; Krause BJ; van Oort I; Witjes AJ; Hoogeveen YL; van Lin EN; Barentsz JO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):712-8. PubMed ID: 22417806 [TBL] [Abstract][Full Text] [Related]
50. Variability of radiotherapy volume delineation: PSMA PET/MRI and MRI based clinical target volume and lymph node target volume for high-risk prostate cancer. Liu LL; Zhu LL; Lu ZG; Sun JD; Zhao J; Wang HF; Xiang ZL Cancer Imaging; 2023 Jan; 23(1):1. PubMed ID: 36600283 [TBL] [Abstract][Full Text] [Related]
51. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[⁶⁸Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Giesel FL; Fiedler H; Stefanova M; Sterzing F; Rius M; Kopka K; Moltz JH; Afshar-Oromieh A; Choyke PL; Haberkorn U; Kratochwil C Eur J Nucl Med Mol Imaging; 2015 Nov; 42(12):1794-800. PubMed ID: 26162799 [TBL] [Abstract][Full Text] [Related]
53. Comparison of 68Ga-PSMA PET/CT and multiparametric MRI for staging of high-risk prostate cancer68Ga-PSMA PET and MRI in prostate cancer. Tulsyan S; Das CJ; Tripathi M; Seth A; Kumar R; Bal C Nucl Med Commun; 2017 Dec; 38(12):1094-1102. PubMed ID: 28957842 [TBL] [Abstract][Full Text] [Related]
54. Detection of recurrent prostate cancer lesions before salvage lymphadenectomy is more accurate with (68)Ga-PSMA-HBED-CC than with (18)F-Fluoroethylcholine PET/CT. Pfister D; Porres D; Heidenreich A; Heidegger I; Knuechel R; Steib F; Behrendt FF; Verburg FA Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1410-7. PubMed ID: 26993315 [TBL] [Abstract][Full Text] [Related]